Subcutaneous apomorphine in Parkinson's disease. 1988

W Poewe, and B Kleedorfer, and F Gerstenbrand, and W Oertel

UI MeSH Term Description Entries
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001058 Apomorphine A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use. Apokinon,Apomorphin-Teclapharm,Apomorphine Chloride,Apomorphine Hydrochloride,Apomorphine Hydrochloride Anhydrous,Apomorphine Hydrochloride, Anhydrous,Apomorphine Hydrochloride, Hemihydrate,Britaject,Apomorphin Teclapharm
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

W Poewe, and B Kleedorfer, and F Gerstenbrand, and W Oertel
April 1989, Journal of neurology, neurosurgery, and psychiatry,
W Poewe, and B Kleedorfer, and F Gerstenbrand, and W Oertel
February 1998, BMJ (Clinical research ed.),
W Poewe, and B Kleedorfer, and F Gerstenbrand, and W Oertel
June 1992, The Medical journal of Australia,
W Poewe, and B Kleedorfer, and F Gerstenbrand, and W Oertel
March 2019, Annals of agricultural and environmental medicine : AAEM,
W Poewe, and B Kleedorfer, and F Gerstenbrand, and W Oertel
November 2020, Journal of neurology,
W Poewe, and B Kleedorfer, and F Gerstenbrand, and W Oertel
December 2022, The Eurasian journal of medicine,
W Poewe, and B Kleedorfer, and F Gerstenbrand, and W Oertel
January 1994, Neurologia (Barcelona, Spain),
W Poewe, and B Kleedorfer, and F Gerstenbrand, and W Oertel
February 1990, Journal of neurology, neurosurgery, and psychiatry,
W Poewe, and B Kleedorfer, and F Gerstenbrand, and W Oertel
September 1989, Lancet (London, England),
W Poewe, and B Kleedorfer, and F Gerstenbrand, and W Oertel
March 1989, Lancet (London, England),
Copied contents to your clipboard!